Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Xigris Sepsis Benefit Defended By FDA In NEJM 

Executive Summary

An FDA analysis of Xigris PROWESS trial data suggests that Lilly's tightening of patient exclusion criteria during the study does not account for greater drug benefit seen after the protocol change

You may also be interested in...



Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says

FDA's analysis of manufacturing process changes for Xigris is the latest indication that some form of a generic biologics approval process is feasible, the Generic Pharmaceutical Association says

Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says

FDA's analysis of manufacturing process changes for Xigris is the latest indication that some form of a generic biologics approval process is feasible, the Generic Pharmaceutical Association says

Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages

Lilly is planning to publish a series of peer-reviewed Xigris journal articles as part of a continued effort to build market acceptance of the sepsis agent

Related Content

UsernamePublicRestriction

Register

PS040548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel